Loss of VHL in mesenchymal progenitors of the limb bud alters multiple steps of endochondral bone development by Mangiavini, Laura et al.
Loss of VHL in mesenchymal progenitors of the limb bud alters 
multiple steps of endochondral bone development
Laura Mangiavini1,2,3,4,#, Christophe Merceron1,2,5,6,#, Elisa Araldi3, Richa Khatri3, Rita 
Gerard-O'Riley2, Tremika LeShan Wilson1,2,3, Erinn B. Rankin3,7, Amato J. Giaccia7, and 
Ernestina Schipani1,2,3,8,*
1Department of Orthopaedic Surgery, Medical School, University of Michigan, Ann Arbor, MI 
48109, USA
2Division of Endocrinology, Department of Medicine, School of Medicine, Indiana University, 
Indianapolis, IN 46202, USA
3Endocrine Unit, Massachusetts General Hospital-Harvard Medical School, Boston, MA 02114, 
USA
4Department of Orthopaedic and Traumatology, Milano-Bicocca University, 20900, Monza (MB), 
Italy
5Inserm, UMRS 791-LIOAD, Centre for Osteoarticular and Dental Tissue Engineering, Group 
STEP ‘Skeletal Tissue Engineering and Physiopathology’, 44042 Nantes, France
6LUNAM, Nantes University, Faculty of Dental Surgery, Nantes, France
7Division of Radiation and Cancer Biology, Department of Radiation Oncology, Stanford 
University, Stanford, CA 94303-5152, USA
8Division of Endocrinology, Department of Medicine, Medical School, University of Michigan, Ann 
Arbor, MI 48109, USA
Abstract
Adaptation to low oxygen tension (hypoxia) is a critical event during development. The 
transcription factors Hypoxia Inducible Factor-1α (HIF-1α) and HIF-2α are essential mediators of 
the homeostatic responses that allow hypoxic cells to survive and differentiate. Von Hippel Lindau 
protein (VHL) is the E3 ubiquitin ligase that targets HIFs to the proteasome for degradation in 
normoxia. We have previously demonstrated that the transcription factor HIF-1α is essential for 
survival and differentiation of growth plate chondrocytes, whereas HIF-2α is not necessary for 
fetal growth plate development. We have also shown that VHL is important for endochondral 
bone development, since loss of VHL in chondrocytes causes severe dwarfism. In this study, in 
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order to expand our understanding of the role of VHL in chondrogenesis, we conditionally deleted 
VHL in mesenchymal progenitors of the limb bud, i.e. in cells not yet committed to the 
chondrocyte lineage. Deficiency of VHL in limb bud mesenchyme does not alter the timely 
differentiation of mesenchymal cells into chondrocytes. However, it causes structural collapse of 
the cartilaginous growth plate as a result of impaired proliferation, delayed terminal 
differentiation, and ectopic death of chondrocytes. This phenotype is associated to delayed 
replacement of cartilage by bone. Notably, loss of HIF-2α fully rescues the late formation of the 
bone marrow cavity in VHL mutant mice, though it does not affect any other detectable 
abnormality of the VHL mutant growth plates. Our findings demonstrate that VHL regulates bone 
morphogenesis as its loss considerably alters size, shape and overall development of the skeletal 
elements.
Keywords
endochondral bone development; limb bud mesenchyme; von Hippel Lindau; Hypoxia Inducible 
Factor
INTRODUCTION
The ability of a cell to adapt to low oxygen tension (hypoxia) is critical both in pathological 
settings such as cancer and ischemia, and in normal development and differentiation [1].
The transcription factors Hypoxia Inducible Factor-1α (HIF-1α) and HIF-2α are crucial 
mediators of the homeostatic responses that allow hypoxic cells to survive and differentiate 
[2]. These proteins trigger a range of autonomous, autocrine, paracrine and endocrine effects 
with the overall goal of increasing oxygen delivery to tissues while decreasing their oxygen 
consumption, and thus promoting cell survival and differentiation [3–5].
HIF is a heterodimeric protein that results from the association between HIF-α and HIF-β 
subunits [6]. Three distinct forms of HIF-α and HIF-β do exist, and they are each the 
product of distinct paralogue genes [7, 8]. Each alpha subunit is able to bind any of the beta 
subunit to form a functional transcription factor. The beta subunit is constitutively 
expressed, whereas the alpha subunit is the oxygen-regulated element of the complex. In 
normoxia, a family of HIF prolyl-4-hydroxylases (PHDs) is responsible for the 
hydroxylation of two proline residues (P402 and P564) in the oxygen dependent degradation 
domain of HIF-1α [9, 10]. The E3 ubiquitin ligase von Hippel-Lindau (VHL) binds to the 
hydroxylated HIF-1α, and targets it to the proteasome for degradation [9, 11]. In hypoxia, 
hydroxylation of HIF-1α is inefficient, and thus HIF-1α migrates to the nucleus, binds 
HIF-1β, and hence promotes transcription of genes that have hypoxia responsive elements in 
their promoter region. The HIF-2α isoform is regulated by oxygen with a modality similar to 
HIF-1α [12].
The importance of VHL for proteolysis of HIF-1α and HIF-2α is highlighted by the finding 
that cells lacking functional VHL are unable to degrade these transcription factors, 
ultimately resulting in their accumulation [9, 11, 13, 14]. However, VHL has also a variety 
of biological activities including control of the cell cycle, regulation of matrix proteins, 
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interaction with the cytoskeleton and with the primary cilia that are HIF-independent [15, 
16].
The fetal growth plate is a suitable model to study cellular adaptation to hypoxia during 
development [17]. Bone can form through two different mechanisms, intramembranous and 
endochondral. While the flat bones of the skull develop from mesenchymal cells that 
directly differentiate into osteoblasts (intramembranous bone formation), the other skeletal 
elements derive from a chondrocyte anlage that is replaced by bone [18–21]. This latter 
process is called endochondral bone development.
During endochondral bone development, mesenchymal cells first condense; cells within 
these condensations next differentiate into chondrocytes and generate the fetal growth plate. 
Growth plate chondrocytes are highly proliferative, and while they divide, they also pile up 
to form a columnar layer. The most distal cells of the columnar layer stop proliferating, exit 
the cell cycle, and differentiate into hypertrophic chondrocytes, which mineralize their 
surrounding matrix. The cartilaginous mold is then invaded by blood vessels and replaced 
by bone at two sites, the primary spongiosa and the secondary ossification center, 
respectively [19, 22, 23]. In parallel to the chondrocyte differentiation process, three-layered 
interzones that will give origin to the prospective synovial joints are specified; formation of 
the synovial space occurs upon cavitation of these interzones [24, 25]. Consistent with its 
avascularity, the murine fetal growth plate displays a gradient of oxygenation with an inner, 
hypoxic region [26].
The VHL/HIF pathway impacts numerous aspects of cartilage and bone biology. In 
particular, during growth plate development, HIF-1α is required for timely differentiation of 
mesenchymal cells into chondrocytes, for chondrocyte survival and for joint specification 
[26, 27]. Therefore, this transcription factor is necessary for endochondral bone 
development. Conversely, HIF-2α is virtually dispensable, as deficiency of HIF-2α causes 
only a modest and transient delay of chondrocyte terminal differentiation [28]. We have also 
recently reported an important role of VHL in endochondral bone development [29]. Mice 
lacking VHL in chondrocytes display a striking growth plate phenotype characterized by 
hypocellularity, impaired proliferation, and increased cell size in the round proliferative 
zone. These features eventually lead to severe dwarfism. Notably, loss of both VHL and 
HIF-1α in chondrocytes causes a growth plate phenotype identical to the one described in 
HIF-1α null animals [26]; HIF-1α is thus epistatic to VHL.
In order to better understand the role of VHL in the early steps of chondrogenesis, we 
genetically deleted VHL in mesenchymal progenitors of the limb bud, i.e. in cells that will 
give origin to the cartilage anlage by differentiating into chondrocytes but are not yet 
committed to the chondrocyte lineage. Our findings demonstrate that loss of VHL in limb 
bud mesenchyme alters multiple steps of endochondral bone development and, thus, they 
provide clear evidence that VHL is a crucial regulator of this process.
MATERIALS AND METHODS
All the experiments were performed using at least three independent biological replicates.
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Generation of Mice
Generation and genotyping of the VHL (FVB/N), HIF-1α (FVB/N) and HIF-2α (C57/B6) 
floxed mice, PRX1-Cre (FVB/N), OSX-Cre (FVB/N) transgenic mice and ROSA26 mT/mG 
(FVB/N) reporter mice have been previously described [26, 30–33]. For all studies, cre-
positive heterozygous floxed mice and cre-negative homozygous floxed mice, respectively, 
were used as controls. We found that the PRX1-Cre or OSX-Cre transgenes per se did not 
affect any of the phenotypes described in this manuscript. Generation of mT/mG mice has 
been previously described [34]. Of note, though in the same genetic background (FVB/N), 
in the study we strictly compared only mutant and control littermates. Moreover, at least 
three mutants and three controls were analyzed in each assay.
All procedures involving mice were performed in accordance with the NIH guidelines for 
use and care of live animals, and were approved by the Indiana University Institutional 
Animal Care and Use Committee (IACUC).
Growth curve, whole mount Alizarin Red S/Alcian Blue staining, routine histology, PAS 
staining, immunohistochemistry, in situ hybridization, TUNEL, Oil Red O staining, 
safranin-O staining and PCNA assay
Mice were weighed and measured at birth, p7, p14 and p21 to generate weight and growth 
curves, respectively. Whole mount Alizarin Red S/Alcian Blue staining was performed at 
birth as previously described [27]. For light microscopy, tissues from E10.5, E12.5, E13.5, 
E14.5, E15.5, E17.5 (delivered by caesarean section), newborn, p5, p17-p24 and 4 months 
were fixed in 4% Paraformaldehyde (PFA)/Phosphate Buffer Saline (PBS) (pH 7.4) for 48h 
at 4°C, and then stored in 70% ethanol at 4°C. Newborn and postnatal specimens were 
decalcified in 20% Ethylenediaminetetraacetic acid (EDTA) pH 7.5 at 4°C for up to 10 days. 
Paraffin blocks were prepared by standard histological procedures. Sections (5-6 mm thick) 
were cut from several levels of the block, and stained with Hematoxylin and Eosin.
For immunohistochemistry detection, paraffin sections from forelimbs of E10.5, E12.5, 
E13.5 and E15.5 mice embryos were treated with sodium citrate buffer pH 6 at 95°C for 10 
minutes. Sections were then incubated with the following primary antibodies: VHL at 1:100 
(BD 556347, BD Biosciences, San Jose, CA, USA), HIF-1α at a 1:100 (MAB1935, R&D 
Systems, Inc, Minneapolis, MN, USA) or HIF-2α at a 1:100 (NB100-122, Novus 
Biologicals, LLC, Littleton, CO, USA) overnight at 4°C. After incubation with the 
appropriate biotinylated secondary antibodies rabbit-anti-mouse (E 0413, Dako North 
America Inc., Carpinteria, CA, USA) or swine-anti-rabbit (E 0431, Dako North America 
Inc., Carpinteria, CA, USA), detection of the binding was carried out using the labeled 
streptavidin biotin (TSA) system following manufacturer’s instructions (Perkin Elmer, 
Shelton CT, USA). Negative controls have been performed by omitting the primary 
antibody.
In situ hybridizations were performed on paraffin sections from hindlimbs and forelimbs of 
E13.5, E14.5, E15.5, p5 and p17 mice using complementary 35S-labeled riboprobes, as 
previously described [27].
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For PAS staining, paraffin sections from hindlimbs of newborn mice were stained using a 
PAS staining kit (Dako North America Inc., Carpinteria, CA, USA) according to the 
manufacturer’s conditions.
TUNEL assay was performed on paraffin sections from hindlimbs of E15.5 and p17-p21 
mice using an "In situ cell death detection" Kit (Roche Diagnostic, Mannheim, Germany). 
Sections were permeabilized with 0.1% TritonX100 in 0.1% sodium citrate; TUNEL assay 
was then carried on according to manufacturer’s instructions.
Oil Red O staining was performed on liver fixed frozen sections at p17. Sections were 
incubated in 0.5% Oil Red O solution (Sigma Aldrich, St Louis, MO, USA) for 10 minutes, 
counterstained with Hematoxylin/Acetic water for 1 minute and coverslipped with aqueous 
mounting medium (Vector Laboratories, Burlingame, CA, USA).
For safranin-O staining, paraffin sections from forelimbs of E12.5, E13.5, E14.5 and E15.5 
embryos were stained with safranin-O/fast green according to standard protocols [35].
PCNA assay was performed on paraffin sections from hindlimbs of p18 mice using the 
PCNA Invitrogen Kit (Invitrogen Corporation, Frederick, MD, USA), according to 
manufacturer’s instructions.
BrdU Incorporation
E15.5 pregnant mice were injected intraperitoneally with 100 µg BrdU/12 µg FdU per gram 
body weight 2 hours prior to sacrifice. After sacrifice, embryo hindlimbs were dissected, 
fixed, and embedded in paraffin, and longitudinal sections across the tibia and femur were 
obtained. To identify actively proliferating cells, nuclei that had incorporated BrdU were 
detected using a Zymed BrdU immunostaining kit (Invitrogen Corporation, Frederick, MD, 
USA). Both total number of cells and BrdU-positive cells where manually counted in the 
Round Proliferative Layer (RPL) and in the Columnar Proliferative Layer (CPL) of the 
developing growth plates; proliferative rates were then calculated as number of BrdU-
positive cells divided by total number of cells.
Cryosections
Hindlimbs, spines and livers were dissected from E15.5, p3 and p17 specimens, fixed in 4% 
PFA/PBS at 4°C for 48h and then stored in 70% ethanol at 4°C. Postnatal specimens were 
decalcified in 20% EDTA pH 7.5 at 4°C for up to 10 days. All the samples were 
subsequently placed in 30% Sucrose/PBS overnight and then embedded in optimum cutting 
temperature (OCT) embedding medium. Samples were sectioned at a thickness of 10 μm 
using a Leica cryostat. Sections were stored at −80°C for later use.
Image Acquisition
Images were acquired with Eclipse E800 (Nikon, Brighton, MI, USA). Additional images 
were captured with a Leica DM LB compound microscope (Leica Microsystems Inc., 
Buffalo Grove, IL, USA). For fluorescent images, frozen sections were dehydrated at RT 
overnight, rinsed in distilled water for 10 minutes and then overlayed with coverslips onto 
Vectashield Hard Set mounting medium with 4′,6-diamidino-2-phenylindole (DAPI) 
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(Vector Laboratories, Burlingame, CA, USA). Photos were taken using filters for Red 
Fluorescent Protein (RFP), fluorescein isothiocyanate (FITC) and DAPI.
Transmission Electron Microscopy (TEM) and Toluidine Blue staining
Growth plates were cleared completely of surrounding soft tissues, fixed in EM fixative 
(2.5% glutaraldehyde, 2.0% PFA, 0.025% calcium chloride in a 0.1 M sodium cacodylate 
buffer [pH 7.4]), and processed for EM. Two sets of consecutive sections were prepared: 1 
µm sections stained with Toluidine Blue (5 minutes) to visualize the tissue morphology; 0.3 
µm sections that were placed on top of grids for EM analysis. Samples were examined with 
a Phillips 301 transmission electron microscope and digital images were captured using an 
AMT (Advanced Microscopy Techniques) CCD camera at magnifications ranging from 
×4500 to ×19,500.
X-Rays
Hindlimbs and forelimbs were analyzed by radiography, using an XPERT 80- L Cabinet X-
ray System (Kevex-90Kv) (Kubtec X-Ray, Milford, CT, USA). Mice were imaged in a 
prone position at p21 using 2.7x magnification for CNTRL mice and 6.6x magnification for 
VHL, HIF1 and VHL-HIF1 mice. The images were acquired through Digicom NC software 
(Kubtec X-Ray, Milford, CT, USA).
Cell Isolation and Culture
Primary chondrocytes were isolated from newborn growth plates of VHL and CNTRL mice, 
respectively and cultured as described [36]. Deletion of Vhlh was confirmed by PCR 
analysis of the genomic DNA extracted from chondrocytes in culture, as previously reported 
[33].
Moreover, primary chondrocyte from newborn VHLf/f growth plates were also isolated for 
adenovirus infection [36]. On day 1 post-plating, adherent VHLf/f chondrocytes were 
infected with adenovirus containing either β-galactosidase or cre-recombinase (Vector 
Biolabs, Philadelphia, PA, USA) to generate wild-type chondrocytes or VHL null cells. All 
cells were incubated at 5% CO2 under humidified atmosphere and media were changed 
every 2-3 days prior to collection.
Photos of cultured cells were taken with a Leica EC3 camera (Leica Microsystems Ltd, 
Switzerland).
dsDNA Quantification: PicoGreen Assay
Cells were rinsed twice with sterile, cold PBS (Cellgro, Mediatech, Inc, Manassas, VA, 
USA) prior to addition of 1 mL diluted lysis buffer, provided in Quant-iT PicoGreen dsDNA 
Assay kit (P7589, Life Technologies, Grand Island, NY, USA). Plates were wrapped in 
aluminum foil and placed at −80°C overnight at minimum. Plates were thawed at room 
temperature; samples were vigorously triturated individually and transferred to DNase-free 
microcentrifuge tubes. Samples and standards were loaded onto black 96-well plates. 
PicoGreen fluorescent nucleic acid stain (from kit) was added and plates were incubated at 
room temperature, protected from light, for 5 minutes. Sample fluorescence was measured 
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using the Synergy Mx microplate reader (BioTek, Winooski, VT, USA) with an excitation 
wavelength of ~480nm and emission wavelength of ~520nm.
Western Blotting
For protein extraction, cells were lysed in buffer containing sodium chloride, Tris, glycerol, 
Nonidet P-40 (Sigma Aldrich, St Louis, MO, USA), EDTA, and protease inhibitors (Roche 
Diagnostic, Mannheim, Germany). Bicinchoninic acid assay was performed for protein 
determination (Thermo Scientific, Rockford, Il, USA). Samples were analyzed by 10% 
SDS-PAGE gels (Bio-Rad Laboratories, Hercules, CA, USA) and subsequently transferred 
to Polyvinylidene fluoride (PVDF) membrane utilizing the BioRad Criterion system. 
Membranes were blocked in 5% milk in Tris-Buffered Saline with Tween 20 (TBST) and 
incubated in 5% milk with TBST at 4°C overnight with the following primary antibodies: 
HIF-1α (NB 100-479, Novus Biologicals, Littlelton, CO, USA) at 1:1000, HIF-2α (AF2997, 
R&D Systems, Inc., Minneapolis, MN, USA) at 1:200, BiP (3177S, Cell Signaling 
Technology, Inc., Danvers, MA, USA) at 1:1000 or p53 (VP-P952, Vector Laboratories, 
Inc., Burlingame, CA, USA) at 1:500. The membranes were then incubated with 
corresponding HRP-conjugated secondary antibodies donkey-anti-rabbit (Cell Signaling 
Technology, Inc., Danvers, MA, USA) or donkey-anti-goat (Santa Cruz Biotechnology, Inc., 
Santa Cruz, CA, USA) at 1:2000 for 1 hour in 5% milk with TBST. The blots were then 
incubated in Amersham ECL Plus Western Blotting System (GE Healthcare Biosciences, 
Pittsburgh, PA, USA), and chemiluminescent bands were visualized via the Image Quant 
LAS-4000 Fuji imaging system (Fujifilm Life Science, Tokyo, Japan). Quantification was 
performed using Image-J software (NIH). α-Tubulin antibody (Cell Signaling Technology, 
Inc., Danvers, MA, USA) was used to normalize protein amount.
Statistical Analysis
Histograms are represented as the mean of the replicates ± SD. Statistical differences were 
analyzed using the Student’s t test. Differences with a p-value <0.05 were considered as 
statistically significant.
RESULTS
Generation of mice lacking VHL in mesenchymal progenitors of the limb bud
In order to define the role of VHL in the mesenchymal cells of the limb bud, we 
conditionally inactivated VHL in cells expressing cre-recombinase under the control of a 
PRX1 enhancer (PRX1-Cre). For this purpose, mice homozygous for the Vhlh conditional 
alleles (2-loxP) were crossed with PRX1-Cre mice to generate PRX1-Cre;VHLf/f mutant 
(VHL) mice and PRX1-Cre;VHLf/+ or VHLf/f control (CNTRL) mice. Of note, PRX1-
Cre;VHLf/+ and VHLf/f mice were phenotypically identical, therefore for the purpose of this 
study they were used indistinctly.
PRX1-Cre mediates efficient cre-recombinase activity in mesenchymal progenitors that 
differentiate both into cartilage and bone, and into the soft tissue surrounding the 
cartilaginous primordia [32, 37]. The expression of PRX1-Cre in cartilage and in the 
surrounding soft tissues was confirmed using mT/mG reporter mice (mTmG) [34]. These 
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mice have loxP sites on either side of a membrane-targeted tandem dimer Tomato (mT) 
cassette, and express red fluorescence in all tissues. When bred to PRX1-Cre mice (PRX-
mTmG), the mT cassette is deleted, allowing expression of the membrane-targeted EGFP 
(mG) cassette located downstream, in the tissues where cre is active. In E15.5 PRX-mTmG 
mice, both growth plate and surrounding soft tissues including the perichondrium displayed 
a positive EGFP signal, concomitant with the loss of the red fluorescent signal, indicating a 
high level of cre activity at these sites (Figure 1).
The VHL conditional allele contains 2-loxP sites flanking the Vhlh promoter and exon 1 
[31]. Recombination of the VHL conditional allele in VHL chondrocytes was confirmed by 
genomic PCR analysis for the recombined (1-loxP) allele (Supplemental Figure 1, Panel A).
As predicted by the current model, an increased accumulation of both HIF-1α and HIF-2α 
proteins was observed by Western blot analysis of whole protein lysate extracted from VHL 
chondrocytes when compared to CNTRL (Supplemental Figure 1, Panel B). This 
accumulation was confirmed at the nuclear level by immunohistochemistry (IHC) on 
histological sections of E15.5 mutant and control growth plates (Supplemental Figure 1, 
Panel C).
Moreover, in agreement with these findings, expression of Vascular Endothelial Growth 
Factor (VEGF) mRNA, a classical downstream target of both HIF-1α and HIF-2α [38], was 
considerably augmented throughout the proliferative zone of the mutant growth plates when 
compared to CNTRL (Supplemental Figure 1, Panel D). VEGF is an important regulator of 
angiogenesis in endochondral bone development, and it is also a chondrocyte survival factor 
[39, 40]. Physiologically, VEGF mRNA is expressed both in hypertrophic chondrocytes, 
and, though at lower levels, in the inner portion of the proliferative zone, i.e. in the hypoxic 
region of the developing growth plate [39, 40].
Last, Transmission Electron Microscopy analysis and Toluidine blue staining of 
chondrocytes in vivo revealed the presence in the mutant cells of lipid droplets and glycogen 
accumulation, which are two hallmarks of VHL null specimens [41] (Supplemental Figure 
1, Panel E: a and b, c and d). Periodic Acid Schiff (PAS) staining confirmed the 
accumulation of glycogen in mutant chondrocytes (Supplemental Figure 1, Panel F).
Taken together, these findings provide clear evidence that VHL was efficiently deleted and 
HIF-1α and HIF-2α were significantly stabilized in mutant growth plate chondrocytes.
Loss of VHL in mesenchymal progenitors of the limb bud generates shorter and 
developmentally delayed fetal bones by impairing proliferation of chondrocytes and by 
delaying their terminal differentiation
Mice with loss of VHL in limb bud mesenchyme were born with the expected mendelian 
frequency. Whole mount Alizarin Red S/Alcian Blue staining performed at birth showed 
that, whereas overall body size was similar (Figure 2: a and b), long bones were shorter, 
thinner and deformed in VHL mice in comparison to CNTRL (Figure 2: c-f), Of note, no 
obvious patterning defect was detectable in mutants (Figure 2: a and b).
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The PRX1-Cre transgenic mouse expresses cre-recombinase at high level in the limb bud 
mesenchyme starting from E9.5, i.e. before mesenchymal condensations form [32]. Loss of 
HIF-1α in mesenchymal progenitors delays early chondrogenesis and joint development 
[27]. We thus asked the question whether loss of VHL affects these two processes.
IHC provided convincing evidence that VHL protein is expressed in wild type limb bud 
mesenchyme at E10.5, and that we had successfully knocked out VHL in mesenchymal cells 
at this early stage of development (Supplemental Figure 2, Panel A: a and b).
However, safranin-O staining of E12.5 forelimb autopods indicated that loss of VHL did not 
accelerate differentiation of mesenchymal progenitors into chondrocytes (Supplemental 
Figure 2, Panel B: a and b).
Consistent with this conclusion, at E13.5 both mutant and control chondrocytes in the 
autopod showed similar morphology, comparable glycosaminoglycans content 
(Supplemental Figure 2, Panel B: c and d), and equivalent levels of expression of Sox9 and 
type II collagen (Col2a1) mRNAs (Supplemental Figure 4, Panel C; a and b, c and d). Sox9 
is the “master” transcription factor of chondrogenesis, and its mRNA is expressed in 
proliferative chondrocytes but not in hypertrophic cells [21]; Col2a1 mRNA is a classical 
chondrogenic marker.
Notably, loss of VHL did not affect the process of joint segmentation either, as suggested by 
the analysis of Growth Differentiation Factor 5 (GDF5) mRNA expression (Supplemental 
Figure 2, Panel C: e and f). GDF5 is one of the earliest markers of joint specification, and it 
can be detected before interzones become histologically evident [42, 43].
Differently from early chondrogenesis, the subsequent steps of endochondral bone 
development were severely altered by loss of VHL. In particular, E13.5 mutant stylopods 
were already considerably smaller than controls, as indicated by H&E staining and by 
Col2a1 mRNA expression (Figure 3, Panel A: a-d). Moreover, chondrocyte terminal 
differentiation was severely delayed in VHL specimens in comparison to CNTRL, as shown 
by the uninterrupted expression of Sox9 mRNA (Figure 3, Panel A: e and f), the smaller 
domain of type X collagen (Col10a1) mRNA (Figure 3, Panel A: g and h), and the lack of 
osteopontin (SPP1) mRNA (Figure 3, Panel A: i and j). Col10a1 is a classical marker of 
hypertrophic chondrocytes, and its mRNA is already detectable immediately before 
hypertrophy occurs; it is then down regulated in the late hypertrophic chondrocytes located 
at the border with the primary spongiosa [21]. SPP1 mRNA is produced by late hypertrophic 
cells [21].
In addition, data collected by routine histology (Supplemental Figure 3: a and b) and by in 
situ hybridization analysis of E14.5 stylopods, namely persistence of Col2a1 mRNA in the 
center of the cartilaginous element and presence of one single domain of Col10a1 mRNA in 
mutant elements (Supplemental Figure 3: c and d, e and f), further supported the notion that 
at this developmental stage mutant hypertrophic chondrocytes, differently from controls, had 
not yet transitioned into late hypertrophic cells, which do not express Col2a1 mRNA and 
display lower amounts of Col10a1 mRNA.
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Last, consistent with the hypothesis that loss of VHL delays endochondral bone 
development, formation of the bone marrow cavity was delayed in mutant specimens in 
comparison to controls (Figure 3, Panel B: a and b), as confirmed by the larger domains of 
Col2a1 and Col10a1 mRNA expression in E15.5 mutant stylopods (Figure 3, Panel B: c and 
d, e and f), and by the persistence in mutants of a safranin-O positive matrix in a region that 
was already occupied by bone marrow in control specimens (Figure 3, Panel B: g and h).
In line with our previous findings obtained in mutant mice in which VHL had been deleted 
in cells already committed to the chondrocyte lineage [29], a significant impairment of 
chondrocyte proliferation in both round proliferative and columnar layers was also detected 
in mutant fetal growth plates, as indicated by BrdU analysis (Figure 4, Panel A). Moreover, 
as previously reported [29], mutant chondrocytes in the round proliferating zone of the fetal 
growth plate were abnormally enlarged with a higher cytoplasm to nucleus ratio (Figure 4, 
Panel B).
In addition to their shortening, loss of VHL in limb bud mesenchyme caused deformities of 
the forelimb zeugopod as shown by H&E (Figure 5, Panel A: a and c), and by in situ 
hybridization analysis for Col2a1 and Col10a1 mRNAs (Figure 5, Panel A: b, d and e) of 
15.5 specimens. Of note, these deformities, which were still detectable postnatally by X-
Rays (Figure 5, Panel B), affected the same bone at the same location, consistently displayed 
the same shape, and had full penetrance and expressivity (data not shown).
Collectively, our findings demonstrate that loss of VHL in limb bud mesenchyme does not 
alter either chondrogenic differentiation of mesenchymal progenitors or joint development, 
but it impairs proliferation of chondrocytes, delays their terminal differentiation and results 
in bone deformities at specific sites.
Loss of VHL in mesenchymal progenitors of the limb bud causes massive chondrocyte 
death associated to complete growth arrest and lack of the secondary ossification center 
in the postnatal growth plate
After birth, mutant mice became overall smaller than control littermates (Figure 6, Panel A 
and B: a); they lost weight (Figure 6, Panel B: b), and eventually died at 4 weeks of age for a 
cause yet to be identified.
Notably, at postnatal time points, loss of VHL blocked the formation of the secondary 
ossification center, and led to the complete disappearance of both the columnar and the 
hypertrophic layers (Figure 7, a-d). This phenotype was likely the result of the severe 
impairment of proliferation and the profound delay of terminal differentiation observed at 
earlier time points. Curiously, islets of hypertrophic cartilage persisted within the bone 
marrow (Figure 7, b and d), which suggests that a very disorganized cartilage-to-bone 
transition occurred in VHL mutants.
Interestingly, Col2a1 mRNA expression was dramatically down regulated in the round 
proliferative chondrocyte layer of the postnatal growth plate (Figure 7: e and f). This 
somehow unusual finding was not due to either chondrocyte hypertrophy or to chondrocyte 
transdifferentiation into fibroblasts, as mutant chondrocytes did not express either Col10a1 
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mRNA (data not shown) or type I collagen (Col1a1) mRNA (Figure 7: g and h), 
respectively, but it was most likely the consequence of massive cell death (Figure 7: i and j). 
Cell death was associated to complete arrest of cell proliferation, as indicated by PCNA 
staining (Figure 7: k and l). Curiously, no sign of chondrocyte death had been detected at 
prenatal time points (data not shown).
Postnatal VHL mutants also displayed a smaller axial skeleton (Figure 6, Panel A) and, 
histologically, a very modest delay of replacement of cartilage by bone in the vertebral 
bodies, though their overall architecture was normal (Supplemental Figure 4, Panel A). This 
quite mild phenotype was not due to ectopic expression of the cre in the axial skeleton, as 
shown by the use of the mTmG reporter (Supplemental Figure 4, Panel B). The lack of 
ectopic expression of cre in the vertebral bodies is consistent with the observation that, 
differently from the postnatal time points, the overall size of the axial skeleton of VHL 
mutants at birth was normal, as shown by whole mount Alizarin Red S/Alcian Blue staining 
(Figure 2: a and b). Thus, the postnatal axial skeleton phenotype of VHL mutants was most 
likely contributed by systemic factors.
Along these lines, mutant mice displayed a liver phenotype characterized by the presence of 
hemorrhagic cysts (Supplemental Figure 5, Panel A: a-c), angiectases, and abnormal 
proliferation of fibroblastoid cells, which were initially located in close proximity to blood 
vessels, but eventually invaded and replaced the liver parenchyma (Supplemental Figure 5, 
Panel A: d-g). Moreover, consistent with the deletion of VHL, we observed a unique 
accumulation of lipids in the mutant hepatocytes by Oil Red O staining (Supplemental 
Figure 5, Panel A: h and i). All in all, these lesions were reminiscent of the 
hemangioblastomas that develop in liver upon specific deletion of VHL in hepatocytes [31]. 
Tissue surveys of the PRX-mTmG mice revealed ectopic activity of cre-recombinase in 
hepatocytes (Supplemental Figure 5, Panel B), which, to our knowledge, has not previously 
been reported.
Importantly, this liver phenotype was not present at birth (Supplemental Figure 5, Panel C), 
but it developed postnatally and could explain, at least in part, the overall decrease of body 
size and the premature death of VHL mutants.
Taken together, our data indicate that the dramatic decrease of body size and weight of VHL 
mutant mice postnatally is most likely the consequence of systemic factors including a 
potential liver failure. However, and most importantly, the postnatal limb phenotype of VHL 
mice appears to be very specific and not contributed by systemic factors for two main 
reasons: first, differently from the long bones, the postnatal vertebral bodies in VHL mutants 
are histologically very similar to controls, except for an extremely mild delay of replacement 
of cartilage by bone; second, no limb abnormalities have been reported upon specific 
deletion of VHL in hepatocytes [31].
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Loss of VHL in mesenchymal progenitors of the limb bud results in a severe bone 
phenotype, which, however, does not significantly contribute to the growth plate 
abnormalities
Since the PRX1-Cre transgene is expressed in the osteochondroprogenitors that give origin 
not only to cartilage but also to bone [32, 37], to be thorough we attempted to study 
trabecular bone in mutant and control tibias around p21 by routine histology, despite the 
premature death of the mutant mice. This analysis revealed a dramatic increase of trabecular 
bone in mutant specimens as shown by X-rays and routine histology (Figure 8). This 
excessive trabecularization was associated to dilated bone marrow blood vessels and to the 
presence of a stromal cell population in between the bony trabeculae with only a few islets 
of hematopoietic cells (Figure 8, Panel B: b). The premature demise of the VHL mutant 
mice around p28 precluded us from pursuing a further and extensive characterization of their 
bone phenotype. Nonetheless, the finding confirmed our previous data obtained in mutant 
mice in which we had specifically deleted VHL in cells of the osteoblast lineage at different 
stages of differentiation [33, 44].
We next asked whether the postnatal growth plate abnormalities observed in VHL mutant 
mice, and in particular the disorganized transition from cartilage to bone, was somehow the 
consequence of their bone phenotype. To specifically address this question, we conditionally 
knocked out VHL in cells of the osteoblast lineage using OSTERIX-Cre transgenic mice 
(OSX-Cre) [45]; we thus generated mutants (OSX-VHLf/f), cre-positive heterozygous 
floxed (OSX-VHLf/+) and cre-negative homozygous floxed (VHLf/f) controls. We then 
analyzed the developing growth plate at multiple time points from E15.5 to 4 months of age 
in all experimental groups.
As expected, mutant mice lacking VHL in cells of the osteoblast lineage dysplayed a 
dramatic accumulation of trabecular bone; conversely, their growth plate phenotype was 
extremely modest and mainly characterized by a quite mild and very transient delay of 
terminal differentiation (Supplemental Figure 6), which is consistent with the notion that in 
OSX-Cre transgenic mice, cre is also expressed in hypertrophic chondrocytes, though at a 
low level [46].
In light of these findings, we can thus conclude that mutant mice lacking VHL in limb bud 
mesenchyme exhibit, as expected, a dramatic bone phenotype, which most likely is not the 
cause of their severe growth plate abnormalities.
Of note, since in the PRX1-Cre transgenic mouse, cre is not active in the endothelium [32, 
47], it is highly unlikely that any of the histological features dysplayed by the VHL mutant 
mice in either cartilage or bone is a consequence of deletion of VHL in endothelial cells.
Loss of HIF-2α in VHL deficient mesenchymal progenitors of the limb bud accelerates the 
replacement of cartilage by bone
In order to identify a possible role for HIF-1α in mediating at least in part the dramatic 
growth plate phenotype secondary to loss of VHL, we generated mice lacking both VHL and 
HIF-1α (VHL-HIF1) in limb bud mesenchyme. Notably, these double mutant mice had a 
dramatically abnormal postnatal growth plate that was virtually indistinguishable from the 
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mutant growth plate of mice lacking exclusively HIF-1α (Supplemental Figure 7). This 
finding shows that HIF-1α is indeed epistatic to VHL, and it thus confirmed what we had 
previously documented in a mutant model in which both proteins had been conditionally 
deleted by using a cre-recombinase driven by a fragment of the Col2a1 promoter [29].
Since also HIF-2α is stabilized in VHL mutant chondrocytes (Supplemental Figure 1, Panel 
B: a and c) we decided to study a possible role of this transcription factor in mediating some 
of the effects secondary to loss of VHL in limb bud mesenchyme. For this purpose, we 
generated mice lacking both VHL and HIF-2α in limb bud mesenchyme (VHL-HIF2). Mice 
were born with the expected mendelian frequency and they were viable, but they also died 
around p28 (data not shown).
Loss of HIF-2α did not correct the delayed hypertrophic differentiation observed in the VHL 
mutant growth plate, as indicated by routine histology and by in situ hybridization analysis 
for Col10a1 mRNA expression (Figure 9, Panel A: a and b, c and d). In addition, mice 
lacking both VHL and HIF-2α still displayed impaired chondrocyte proliferation, and 
massive postnatal cell death (Figure 9, Panel B and data not shown). Moreover, they had no 
histological evidence of formation of the secondary ossification center (data not shown).
However, loss of HIF-2α rescued the timely formation of the bone marrow cavity (Figure 9, 
Panel C) and accelerated the replacement of cartilage by bone with, consequently, complete 
disappearance of the hypertrophic layer at an even earlier time point than in VHL single 
mutants, as indicated by routine histology and by in situ hybridization analysis for Col10a1 
mRNA expression (Figure 9, Panel D: a,c,e,g and b,d,f,h). This finding, which was 
somehow unexpected as loss of HIF-2α in limb bud mesenchyme determines only a modest 
and transient delay in chondrocyte terminal differentiation [28], suggests that HIF-2α may 
indeed have a fine tuning role at the interface between cartilage and bone.
Loss of VHL impairs proliferation and increases accumulation of BiP protein in 
chondrocytes in vitro
In order to start dissecting out the complex in vivo phenotype of mutant growth plate lacking 
VHL, we performed a series of in vitro analysis. For this purpose, we isolated chondrocytes 
from VHLf/f newborn mice as described in Materials and Methods. We next infected them 
with either β-galactosidase or cre-recombinase adenoviral constructs in order to obtain wild 
type (β-gal) and VHL null (cre) chondrocytes, respectively.
Cell density was considerably decreased in VHL null chondrocyte cultures; in addition, 
morphology of mutant cells appeared to be substantially different from controls, as VHL 
null chondrocytes had lost the classical “cobblestone” appearance and had rather assumed an 
elongated, fibroblastoid shape (Figure 10, Panel A). Analysis of DNA accumulation by 
Picogreen assay confirmed that loss of VHL had significantly impaired chondrocyte 
proliferation in vitro (Figure 10, Panel B) [48].
An extensive literature has suggested a complex relationship between the tumor suppressor 
gene p53 and VHL, which is often context-dependent [49–51]. Since the growth arrest 
observed in VHL mutant chondrocytes could in principle be mediated by stabilization of p53 
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in these cells, we analyzed accumulation of p53 protein in whole cell lysate of newborn 
chondrocytes isolated from mutant and control growth plate chondrocytes. Interestingly, p53 
protein was not detectable in control chondrocytes, as also previously reported by others 
[52] and, more importantly, its expression was not up regulated in mutant chondrocytes 
(data not shown).
It has been reported that endoplasmic reticulum (ER) stress halts chondrocyte proliferation 
and differentiation and causes their death [50, 53–55]; moreover, VHL has been recently 
localized in the ER [16, 56]. We thus asked the question whether loss of VHL activates the 
unfolded protein response (UPR) in chondrocytes in vitro. For this purpose, we analyzed 
expression of the Binding immuglobulin Protein (BiP or GRP78), which is a marker of UPR 
[57]. Notably, levels of BiP expression were significantly higher in VHL null chondrocytes 
when compared to controls (Figure 10, Panel C), which suggests that ER stress could be one 
of the pathogenetic events involved in the generation of the complex growth plate phenotype 
caused by loss of VHL in mesenchymal progenitors.
DISCUSSION
In this study, we report the first conditional knockout of VHL in mesenchymal progenitors 
of the limb bud, i.e. in cells not yet committed to the chondrocyte lineage. Deficiency of 
VHL in limb bud mesenchyme does not alter the timely differentiation of mesenchymal cells 
into chondrocytes. However, it causes structural collapse of the cartilaginous growth plate as 
a result of impaired proliferation, delayed terminal differentiation and ectopic death of 
chondrocytes. This phenotype is associated to delayed replacement of cartilage by bone. 
Loss of HIF-2α fully rescues the late formation of the bone marrow cavity in VHL mutant 
mice, though it does not affect any other detectable abnormality of the VHL mutant growth 
plates. Our findings demonstrate that VHL regulates bone morphogenesis as its loss 
considerably alters size, shape and overall development of the skeletal elements.
Interestingly, the growth plate phenotype of mutant mice lacking VHL in limb bud 
mesenchyme is definitively more severe than the one we reported upon deletion of VHL in 
already differentiated chondrocytes [29]. Moreover, our novel mouse model displays unique 
features, including a dramatic delay of hypertrophy as well as a massive postnatal 
chondrocyte death. We do not exactly know why the two mutant mice differ from each 
other, but it is tempting to speculate that both the diverse spatial and temporal distribution of 
the cre-recombinase and the potential differences in the efficiency of deletion of the floxed 
allele are factors that could contribute to generate the phenotypic differences we detected 
between the two mutant lines.
The analysis of VHL mutant bones also revealed a series of intriguing paradoxes. In 
particular, a delay of terminal differentiation similar to the one observed in VHL deficient 
mice has also been described in mice lacking HIF-1α either in limb bud mesenchyme [27] or 
in chondrocytes [26, 40]. This apparent resemblance, however, is most likely the result of 
profoundly different molecular and/or cellular mechanisms. Along these lines, it is important 
to note that loss of HIF-1α in limb bud mesenchyme delays differentiation of mesenchymal 
progenitors into chondrocytes, and, thus, it is highly probable that this initial delay of early 
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chondrogenesis contributes to slow down hypertrophy. Conversely, VHL does not affect the 
initial steps of chondrogenesis. In addition, loss of HIF-1α in both limb bud mesenchyme 
and in chondrocytes causes a massive cell death phenotype in the fetal growth plate that is 
not initially present in the VHL mutants.
Though we yet do not know why chondrocytes lacking VHL display a significant delay of 
hypertrophy, however, in this study we provide evidence that this phenotype is not due to 
stabilization of HIF-2α, since it is not corrected by HIF-2α deletion.
The impairment of chondrocyte proliferation and the growth arrest we observed in VHL 
mutants is also paradoxical and surprising since VHL is a tumor suppressor gene, but it is 
well in agreement with previous findings by us and others [29, 58–60]. In addition, it is 
consistent with the notion that HIF-1α stabilization slows down cell proliferation [12], 
probably as part of a complex homeostatic response whose ultimate goal is likely to keep 
oxygen consumption in check. Interestingly, however, VHL has been reported to inhibit 
progression through the cell cycle in a HIF-1α-independent fashion [58]. It is thus possible 
that the decreased proliferation first and the virtual growth arrest later observed in VHL 
mutant growth plates could be the result of either HIF-1α-dependent or HIF-1α-independent 
VHL functions.
Loss of VHL, delays blood vessel invasion and the formation of both the primary and 
secondary ossification centers. This is another paradoxical finding since vascularization of 
the cartilage template, which is a required step in endochondral bone development, depends 
largely on VEGF, i.e. a classical downstream target of the HIF signaling pathway [38]. The 
delayed blood vessel invasion is, however, consistent with the overall delay of chondrocyte 
hypertrophy observed in VHL mutant bones. Moreover, it further highlights the intrinsic 
resistance of quiescent or proliferative cartilage to be invaded by blood vessels, despite 
increased expression of VEGF [29, 61].
Along the line of paradoxical findings, postnatal VHL chondrocytes display a severe cell 
death phenotype despite the stabilization of HIF-1α, which is a survival factor in the 
developing growth plate.
Lastly, loss of HIF-2α in the context of VHL mutant mice dramatically accelerates the 
replacement of cartilage by bone, but loss of HIF-2α in limb bud mesenchyme causes a 
transient and modest delay in hypertrophy mainly due to an impairment of differentiation of 
hypertrophic chondrocytes into late hypertrophic cells [28].
To this end, we do not have a full understanding of these paradoxes; however, our in vitro 
findings suggest that ER stress may be a contributing factor to the complex phenotype of 
VHL mutant growth plates. Along these lines, it has been shown that ER stress is an 
important pathogenetic event in some chondrodysplasias [50, 54, 55]. Moreover, the VHL 
protein has been associated to the ER [16, 56]. In our study, we report, for the first time to 
our knowledge, that deletion of VHL leads, with yet unknown mechanisms, to accumulation 
of BiP, a classical marker of UPR.
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Of note, it has been recently reported that VHL regulates Sox9 expression in pancreas [62]. 
Moreover it is also known that ectopic expression of Sox9 in growth plate causes delayed 
terminal differentiation and cartilage vascularization associated with reduced bone growth 
[63, 64]. Therefore, a role of Sox9 in mediating some of the abnormal features we observe in 
VHL mutant growth plates cannot be excluded at this stage of investigation.
In conclusion, we demonstrated that VHL plays an important role in chondrocyte 
differentiation and survival; further studies will be necessary to unveil the detailed 
molecular mechanisms that lead to the severe abnormalities of endochondral bone 
development observed in mutant mice lacking VHL in mesenchymal progenitors of the limb 
bud.
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Refer to Web version on PubMed Central for supplementary material.
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Highlights
• VHL is a key regulator of endochondral bone development and bone 
morphogenesis.
• Loss of VHL does not alter the transition from mesenchymal cells into 
chondrocytes.
• Loss of VHL impairs chondrocyte proliferation and delays hypertrophy.
• Loss of VHL results in bone deformities in selective sites.
• Loss of VHL causes chondrocyte death in postnatal growth plates.
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Figure 1. PRX1-Cre expression in fetal growth plate
a-f. Detection of fluorescence in frozen sections of tibias isolated from E15.5 mTmG (upper 
panels) and PRX-Cre-mTmG (lower panels) mice, respectively. The following abbreviations 
are used: mT, Membrane-targeted tandem dimer Tomato (a and b); mG, Membrane-targeted 
EGFP (c and d); DAPI, 4’,6-diamidino-2-phenylindole counterstain (blue nuclei) (e and f). 
(Bar=250µm).
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Figure 2. Macroscopic appearance of VHL mice at birth
a,b. Whole mount Alizarin Red S/Alcian blue staining of CNTRL (a) and VHL (b) 
newborns mice. (Bar=50 mm).
c-f. Whole mount Alizarin Red S/Alcian blue staining of forelimbs (upper panels) and 
hindlimbs (lower panels) of CNTRL (c and e) and VHL (d and f) mice. The arrow in (d) 
points at the radius deformity. (Bar=50 mm).
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Figure 3. Prenatal growth plate phenotype in VHL mice
A. Delayed terminal differentiation. a,b. H&E staining of E13.5 humerus from CNTRL 
(a) and VHL (b) specimens. (Bar=250µm).
c-j. In situ hybridization for detection of Col2a1 (c and d), Sox9 (e and f), Col10a1 (g and h) 
and SPP1 (i and j) mRNAs in E13.5 CNTRL (upper row) and VHL (lower row) specimens. 
Dark-field images are shown. (Bar=250µm).
B. Delay of bone marrow cavity formation a,b. H&E staining of E15.5 humerus isolated 
from CNTRL (a) and VHL (b) mice. (Bar=250µm).
c-f. In situ hybridization for detection of Col2a1 (c and d) and Col10a1 (e and f) mRNAs in 
E15.5 CNTRL (upper row) and VHL (lower row) samples. Bright-field images are shown. 
(Bar=250µm).
g,h. Safranin-O staining of E15.5 humerus isolated from CNTRL (g) and VHL (h) mice. 
(Bar=250µm).
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Figure 4. Impaired proliferation and abnormal morphology of VHL chondrocytes
A. Chondrocyte proliferation rate in fetal VHL growth plates. a-c. BrdU assay of E15.5 
proximal epiphyses of tibia isolated from CNTRL (a) and VHL (b) mice; quantification of 
the data is shown in (c) (*: p-value <0.05; ***: p-value <0.001). The lines in (a and b) 
highlight the growth plate and separate the RPL from the CPL. The following abbreviations 
are used: RPL, Round Proliferative Layer; CPL, Columnar Proliferative Layer. 
(Bar=250µm).
B. “Atypical” chondrocytes in absence of VHL. a,b. H&E staining of E17.5 distal 
humerus in CNTRL (a) and VHL (b) samples. The arrows in (b) point at atypical 
chondrocytes. (Bar=250µm).
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Figure 5. Radius deformity in VHL mice
A. Histological appearance of the radius deformity. a,c. H&E staining of histological 
sections of E15.5 forelimb isolated from CNTRL (a) and VHL (c) mice. (Bar=250µm).
b,d,e. In situ hybridization for detection of Col2a1 (b and d) and Col10a1 (e) mRNAs in 
CNTRL (b) and VHL (d and e) specimens. Bright-field pictures are shown. The arrows in 
(c-e) indicate the deformity of the radius. (Bar=250µm).
B. Postnatal persistence of the radius deformity. a,b. X-rays pictures of p21 forelimb 
isolated from CNTRL (a) and VHL (b) mice. The arrow in (b) indicates the deformity of the 
radius. (Bar=1 cm).
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Figure 6. Postnatal growth arrest of VHL mice
A. Macroscopic appearance of VHL mice. a,b. Photograph of p21 CNTRL (a) and VHL 
(b) mice.
B. Growth curve of VHL mice. a,b, Length (a) and weight (b) curves of CNTRL and VHL 
mice from p0 to p21. (*: p-value <0.05; **: p-value <0.01).
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Figure 7. Postnatal growth plate collapse and massive cell death in VHL mice
a-d. H&E staining of p18 distal femur in CNTRL (a) and VHL (b) specimens. Higher 
respective magnification is shown in panels (c and d). The arrow in (d) indicates the 
persistence of hypertrophic cartilage within the bone marrow. (Bar=250µm).
e-h. In situ hybridization for detection of Col2a1 (e and f) and Col1a1 (g and h) mRNAs in 
CNTRL (e and g) and in VHL (f and h) p18 distal femur specimens. Dark-fields are shown. 
(Bar=250µm).
i,j. TUNEL assay in p18 distal femur of CNTRL (i) and VHL (j) specimens. The lines on 
each panel highlight the growth plate. (Bar=250µm).
k,l. PCNA staining of histological sections of p18 distal epiphyses of femur isolated from 
CNTRL (k) and VHL (l) mice. The lines on each panel highlight the growth plate. 
(Bar=250µm).
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Figure 8. Bone phenotype in VHL mice
A. Radiological appearance of VHL hindlimbs. a,b. X-rays pictures of p21 hindlimb 
isolated from CNTRL (a) and VHL (b) mice. (Bar=1 cm).
B. Histological appearance of VHL bone. a,b. H&E staining of p17 tibias isolated from 
CNTRL (a) and VHL (b) mice.
The arrow in (b) points at a dilated blood vessel; the circle in (b) highlights stromal cells in 
between the bony trabeculae. (Bar=250µm). Please, note the presence of cartilaginous 
remnants in VHL bone, which could be suggestive of impaired resorption.
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Figure 9. Growth plate phenotype of VHL-HIF2 mice
A. Delayed terminal differentiation. a,b. H&E staining of E13.5 humerus isolated from 
CNTRL (a) and VHL-HIF2 (b) mice. (Bar=250µm).
c,d. Detection of Col10a1 mRNA by in situ hybridization analysis of E13.5 humerus 
isolated from CNTRL (c) and VHL-HIF2 (d) mice. Bright-field images are shown. 
(Bar=250µm).
B. Postnatal massive cell death. a,b. TUNEL assay of p21 distal femur and proximal tibia 
isolated from CNTRL (a) and VHL-HIF2 (b) mice, respectively. The lines on each panel 
define the joint limits. (Bar=250µm).
C. Partial rescue of bone marrow cavity formation. a-d. H&E staining of E15.5 humerus 
isolated from CNTRL (a), HIF2 (b), VHL (c) and VHL-HIF2 (d) mice. The rectangles on 
each panel outline the location of the putative bone marrow cavity. (Bar=250µm). Please, 
note the very modest delay of terminal differentiation in HIF-2 mice.
D. Premature disappearance of the hypertrophic layer. a,c,e,g. H&E staining of p5 distal 
growth plate of humerus isolated from CNTRL (a), HIF2 (c), VHL (e) and VHL-HIF2 (g) 
mice. (Bar=250µm).
b,d,f,h. Detection of Col10a1 mRNA by in situ hybridization analysis of p5 distal growth 
plate of humerus isolated from CNTRL (b), HIF2 (d), VHL (f), VHL-HIF2 (h) mice. Dark-
field images are shown. (Bar=250µm).
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Figure 10. In vitro phenotype of chondrocytes lacking VHL
A. Abnormal morphology of VHL null chondrocytes. a,b. Microscopic pictures of wild 
type (β-gal) (a) and VHL null (cre) (b) chondrocytes. (Bar=250µm).
B. Growth arrest of VHL null chondrocytes. Picogreen assays in wild type (β-gal) and 
VHL null (cre) chondrocytes. (*: p-value <0.05).
C. Accumulation of BiP in absence of VHL. a,b. Western blot analysis of BiP in protein 
lysate from wild type (β-gal) and VHL null (cre) chondrocytes. α-Tubulin was used as a 
loading control. Quantification of the data is shown in (b) (*: p-value <0.05).
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